A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: An observational database study

International Journal of Clinical Practice

Volumn 64, Issue 12, 2010, Pages 1609-1618

  Gordon, J ^a,b   Pockett, R D ^c   Tetlow, A P ^c   McEwan, P ^c   Home, P D ^d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c Cardiff Research Consortium   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PREMIX INSULIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; INSULINS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; TREATMENT OUTCOME; WEIGHT GAIN; YOUNG ADULT;

EID: 78349266799     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02520.x     Document Type: Article

References (31)

1. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31 (Suppl. 1): S12-54.
2. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128: 165-75.
3. Schreiber SA, Haak T,. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007; 9: 31-8.
4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
5. National Institute for Health and Clinical Excellence. Type 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 Diabetes. Clinical guideline 87. (accessed May 2009).
6. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-8.
7. Turner HE, Matthews DR,. The use of fixed-mixture insulins in clinical practice. Eur J Clin Pharmacol 2000; 56: 19-25.
8. Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-9.
9. Goldman-Levine JD, Lee KW,. Insulin detemir-a new basal insulin analog. Ann Pharmacother 2005; 39: 502-7.
10. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-9.
11. Raskin PR, Hollander PA, Lewin A, et al. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med 2007; 18: 56-62.
12. Sun P, Wang R, Jacober S,. The effectiveness of insulin initiation regimens in patients with type 2 diabetes mellitus: a large national medical records review study comparing a basal insulin analogue to premixed insulin. Curr Med Res Opin 2007; 23: 3017-23.
13. Ilag LL, Kerr L, Malone JK, Tan MH,. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 2007; 29: 1254-70.
14. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-16.
15. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-30.
16. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-47.
17. Meneghini LF, Rosenberg KH, Koenen C, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007; 9: 418-27.
18. Dornhorst A, Luddeke HJ, Sreenan S, et al. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008; 62: 659-65.
19. Bourke A, Dattani H, Robinson M,. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004; 12: 171-7.
20. Sharplin P, Gordon J, Peters JR, et al. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study. Cardiovasc Diabetol 2009; 8: 3.
21. Sharplin P, Gordon J, Peters JR, et al. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis. Cardiovasc Diabetol 2009; 8: 9.
22. Brown PJ, Warmington V, Laurence M, Prevost AT,. Randomised crossover trial comparing the performance of Clinical Terms Version 3 and Read Codes 5 byte set coding schemes in general practice. BMJ 2003; 326: 1127.
23. National Health Service. The Quality and Outcomes Framework 2006/07. (accessed August 2009).
24. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
25. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-5.
26. Makimattila S, Nikkila K, Yki-Järvinen H,. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999; 42: 406-12.
27. Raskin P, Gylvin T, Weng W, Chaykin L,. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009; 25: 542-8.
28. Home PD, Fritsche A, Schinzel S, Massi-Benedetti M,. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 2010; 12: 772-9.
29. IMS data from IMS Health MIDAS Retail and Hospital-IU Year 2008, October 2009 update.
30. Lehman R, Krumholz HM,. Tight control of blood glucose in long standing type 2 diabetes. BMJ 2009; 338: b800.
31. Mullins P, Sharplin P, Yki-Järvinen H, et al. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29: 1607-19.